- InstantOn purchase
- Full bookAll chapters
- Any devicePC, tablet, phone
- SecureSSL checkout
Reducing Race Differences in Direct-to-Consumer Pharmaceutical Advertising: The Case for Regulation
by Classics Books & Gifts
Lowest price online, guaranteed. One-time payment, no subscription.
Download link emailed instantly after payment, 24/7
Your download link is sent to the email you enter. Double-check it before completing your order.
File issue? We replace it or refund you, no questions asked.
You'll receive a download link by email immediately after checkout.
Send us the book cover via live chat and we'll request it for you. Typical response time: 10 minutes.
What's inside
Reducing health disparities by increasing access to health information is a national health policy priority. Evidence exists that direct-to-consumer pharmaceutical advertising (DTCA) is effective in educating consumers about health issues. However, racial disparities exist in such advertising. In 2009, the Food and Drug Administration (FDA) issued a report that included recommendations for enhancing the ability of DTCA to reach disadvantaged populations, including racial and ethnic minorities. Reducing Race Differences in Direct to Consumer Pharmaceutical Advertising compares the pharmaceutical advertisements placed in five popular women’s magazines published prior to and following the 2009 FDA report to assess the impact of these recommendations on the content and appearance of advertisements placed in magazines of differing racial orientation. From a health policy perspective, the results are disappointing. The FDA recommendations had no impact on the frequency or content of the DTCA appearing in White-oriented versus Black-oriented magazines. In fact, far fewer drugs used to treat life-threatening conditions were advertised in Black-oriented magazines after the 2009 FDA recommendations. The book concludes that enhancing the educational and motivational value of DTCA will require more than a set of recommendations. The results shed light on the pharmaceutical industry’s compliance with both hard and soft regulation. Neither federal recommendations nor industry guidelines resulted in the changes to DTCA envisioned by the FDA. Regulatory action is necessary to ensure that pharmaceutical companies develop advertising campaigns that not only promote their products, but also positively impact the health outcomes of those who read their ads.
About the Author
Stephany De Scisciolo is senior executive with a national nonprofit dedicated to improving the health and well-being of disadvantaged communities and those that live within them. Teresa L. Scheid is professor of sociology at the University of North Carolina at Charlotte.
| Author | Stephany De Scisciolo, Teresa L. Scheid |
| ISBN-13 | 9781498574174 |
| Publisher | Bloomsbury Publishing |
| Publication Date | 08/31/2018 |
| Page Count | 140 pages |
From checkout to chapter one in seconds
Check out securely
Pay by card or wallet. Use an email address you can access right now.
Get your link
Your download link arrives by email the moment your payment clears, 24/7.
Read anywhere
Open it on your laptop, tablet or phone. Save it and keep it.
Smarter than paying full price
Authorised by publisher: licensed copy, never pirated.
Less than Amazon Kindle, with our lowest-price guarantee.
Delivered the moment your payment clears, day or night.
Complete edition: every chapter, no missing pages.
Good to know
How do I receive my ebook?
Right after checkout we email you a download link. Check your spam folder if it doesn't arrive within a few minutes.
Which devices can I read it on?
Any computer, tablet or phone. PDF opens in any browser or free reader app.
I entered the wrong email. What now?
Contact us via live chat with your order number and we'll resend the link to the right address.
What if there's a problem with the file?
We'll replace it or refund you within 30 days, no questions asked.